<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00785941</url>
  </required_header>
  <id_info>
    <org_study_id>13933</org_study_id>
    <secondary_id>CP13-0502</secondary_id>
    <secondary_id>I5A-IE-JAEI</secondary_id>
    <nct_id>NCT00785941</nct_id>
  </id_info>
  <brief_title>A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available</brief_title>
  <official_title>Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 Administered Every Other Week in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if IMC-A12 is safe for patients, and also to&#xD;
      determine the best dose of IMC-A12 to give to patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to establish the safety profile and maximum tolerated dose (MTD)&#xD;
      of the anti-IGF-IR monoclonal antibody IMC-A12 administered every other week in patients with&#xD;
      advanced solid tumors who no longer respond to standard therapy or for whom no standard&#xD;
      therapy is available.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax), cohorts 1, 2, 3, 4, and 5</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin), cohorts 1, 2, 3, 4, and 5</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under concentration (AUC), cohorts 1, 2, 3, 4, and 5</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t 1/2), cohorts 1, 2, 3, 4, and 5</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (Cl) rate drug is completely removed, cohorts 1, 2, 3, 4, and 5</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vss) at steady state, cohorts 1, 2, 3, 4, and 5</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-IMC-A12 Antibody Assessment (immunogenicity)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor size from Baseline Measurement</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>IMC-A12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive intravenous infusions of IMC-A12, with the dose depending on which cohort they are enrolled into a minimum of three patients will be enrolled in each Cohort. When all patients complete a cohort, dose escalation to the next Cohort will occur.&#xD;
A treatment cycle will consist of IMC-A12 administered intravenously, once every other week for 4 weeks, for a total of 2 doses; followed by a 2-week observation period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-A12</intervention_name>
    <description>Cohort 1&#xD;
6 mg/kg I.V., once every other week for 4 weeks</description>
    <arm_group_label>IMC-A12</arm_group_label>
    <other_name>Cixutumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-A12</intervention_name>
    <description>Cohort 2&#xD;
10 mg/kg I.V., once every other week for 4 weeks</description>
    <arm_group_label>IMC-A12</arm_group_label>
    <other_name>Cixutumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-A12</intervention_name>
    <description>Cohort 3&#xD;
15 mg/kg I.V., once every other week for 4 weeks</description>
    <arm_group_label>IMC-A12</arm_group_label>
    <other_name>Cixutumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-A12</intervention_name>
    <description>Cohort 4&#xD;
21 mg/kg I.V., once every other week for 4 weeks</description>
    <arm_group_label>IMC-A12</arm_group_label>
    <other_name>Cixutumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-A12</intervention_name>
    <description>Cohort 5&#xD;
27 mg/kg I.V., once every other week for 4 weeks</description>
    <arm_group_label>IMC-A12</arm_group_label>
    <other_name>Cixutumumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients with histopathologically-documented, measurable, advanced primary or&#xD;
             recurrent solid tumors who no longer respond to standard therapy or for whom no&#xD;
             standard therapy is available&#xD;
&#xD;
          -  A life expectancy of &gt;3 months&#xD;
&#xD;
          -  Adequate hematologic function&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Use of effective contraception, if procreative potential exists.&#xD;
&#xD;
          -  At least 28 days must have elapsed from major surgery, prior chemotherapy, prior&#xD;
             treatment with an investigational agent or device, prior radiation therapy (palliative&#xD;
             radiation therapy is allowed), an open biopsy, or a significant traumatic injury to&#xD;
             allow for adequate recovery&#xD;
&#xD;
          -  At least 6 weeks must have elapsed from nitrosoureas, mitomycin C, or monoclonal&#xD;
             antibody therapy to allow for adequate recovery&#xD;
&#xD;
          -  Accessible for treatment and follow-up. Patients enrolled in this trial must be&#xD;
             treated at the participating center&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Any concurrent malignancy other than non-melanomatous skin cancer or carcinoma in situ&#xD;
             of the cervix. Patients with a previous malignancy but without evidence of disease for&#xD;
             â‰¥3 years will be allowed to enter the trial&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to:&#xD;
&#xD;
               -  ongoing or active infection requiring parenteral antibiotics&#xD;
&#xD;
               -  symptomatic congestive heart failure (class III or IV of the New York Heart&#xD;
                  Association classification for heart disease)&#xD;
&#xD;
               -  unstable angina pectoris, angioplasty, stenting, or myocardial infarction within&#xD;
                  6 months&#xD;
&#xD;
               -  uncontrolled hypertension (systolic blood pressure &gt;160 mm Hg, diastolic blood&#xD;
                  pressure &gt;100 mm Hg, found on two consecutive measurements separated by a 1-week&#xD;
                  period despite adequate medical support)&#xD;
&#xD;
               -  clinically significant cardiac arrhythmia (multifocal premature ventricular&#xD;
                  contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or&#xD;
                  requires treatment [National Cancer Institute {NCI}-Common Terminology Criteria&#xD;
                  for Adverse Events {CTCAE}, Version 3.0, grade 3] or asymptomatic sustained&#xD;
                  ventricular tachycardia)&#xD;
&#xD;
               -  psychiatric illness/social situations that would compromise patient safety or&#xD;
                  limit compliance with study requirements&#xD;
&#xD;
               -  patients with symptomatic brain metastases (patients with a history of brain&#xD;
                  metastases must be clinically stable and not taking steroids; anticonvulsants are&#xD;
                  allowed)&#xD;
&#xD;
          -  A serious or nonhealing active wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Known human immunodeficiency virus-positive&#xD;
&#xD;
          -  A history of a hemorrhagic or thrombotic disorder within 9 months&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  A history of prior treatment with other agents specifically targeting IGFRs.&#xD;
&#xD;
          -  Known diabetes&#xD;
&#xD;
          -  Inability or unwillingness to interrupt steroidal or hormonal therapy for the duration&#xD;
             of treatment with IMC-A12&#xD;
&#xD;
          -  A positive anti-IMC-A12 antibody response&#xD;
&#xD;
          -  A history of allergic reactions to monoclonal antibodies or other therapeutic proteins&#xD;
&#xD;
          -  Employees of the investigator or study center with direct involvement in this study or&#xD;
             other studies under the direction of the investigator or study center, as well as&#xD;
             family members of the employees&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E-mail: ClinicalTrials@ ImClone.com</last_name>
    <role>Study Chair</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>November 4, 2008</study_first_submitted>
  <study_first_submitted_qc>November 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2008</study_first_posted>
  <last_update_submitted>October 12, 2011</last_update_submitted>
  <last_update_submitted_qc>October 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumors</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

